Andrew Tieniber

Andrew Tieniber

Auto-generated profile, based on publicly available information

Andrew Tieniber

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ATAndrew D. Tieniber
Andrew D. Tieniber
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
GVGerardo A. Vitiello
Gerardo A. Vitiello
MEMark S. Etherington
Mark S. Etherington
RDRonald P. DeMatteo
Ronald P. DeMatteo
Targeted therapy with a tyrosine kinase inhibitor (TKI) such as imatinib is effective in treating gastrointestinal stromal tumor (GIST), but it is rarely curative. Despite the presence of a robust immune CD8+ T-cell infiltrate, combining a TKI with immune-checkpoint blockade (ICB) in advanced GIST has achieved only modest effects. To identify limitations imposed by imatinib on the antitumor immune response, we performed bulk RNA sequencing (RNA-seq), single-cell RNA-seq, and flow cytometry to phenotype CD8+ T-cell subsets in a genetically engineered mouse model of GIST. Imatinib reduced the frequency of effector CD8+ T cells and increased the frequency of naïve CD8+ T cells within mouse GIST, which coincided with altered tumor chemokine production, CD8+ T-cell recruitment, and reduced CD8+ T-cell intracellular PI3K signaling. Imatinib also failed to induce intratumoral T-cell receptor (TCR) clonal expansion. Consistent with these findings, human GISTs sensitive to imatinib harbored fewer effector CD8+ T cells but more naïve CD8+ T cells. Combining an IL15 superagonist (IL15SA) with imatinib restored intratumoral effector CD8+ T-cell function and CD8+ T-cell intracellular PI3K signaling, resulting in greater tumor destruction. Combination therapy with IL15SA and ICB resulted in the greatest tumor killing and maintained an effector CD8+ T-cell population in the presence of imatinib. Our findings highlight the impact of oncogene inhibition on intratumoral CD8+ T cells and support the use of agonistic T-cell therapy during TKI and/or ICB administration.

27 March 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
FRFerdinand Rossi
Ferdinand Rossi
MLMengyuan Liu
Mengyuan Liu
ATAndrew Tieniber
Andrew Tieniber
MEMark S. Etherington
Mark S. Etherington
AHAndrew Hanna
Andrew Hanna
RDRonald P. DeMatteo
Ronald P. DeMatteo
Purpose: To create an in vivo model of PDGFRA D842V-mutant gastrointestinal stromal tumor (GIST) and identify the mechanism of tumor persistence following avapritinib therapy. Experimental Design: We created a patient-derived xenograft (PDX) of PDGFRA D842V-mutant GIST and tested the effects of imatinib, avapritinib, and ML-7, an inhibitor of myosin light-chain kinase (MYLK). Bulk tumor RNA sequencing and oncogenic signaling were evaluated. Apoptosis, survival, and actin cytoskeleton were evaluated in GIST T1 cells and isolated PDX cells in vitro. Human GIST specimens were analyzed for MYLK expression. Results: The PDX was minimally responsive to imatinib but sensitive to avapritinib. Avapritinib therapy increased tumor expression of genes related to the actin cytoskeleton, including MYLK. ML-7 induced apoptosis and disrupted actin filaments in short-term cultures of PDX cells and decreased survival in GIST T1 cells in combination with imatinib or avapritinib. Combined therapy with ML-7 improved the antitumor effects of low-dose avapritinib in vivo. Furthermore, MYLK was expressed in human GIST specimens. Conclusions: MYLK upregulation is a novel mechanism of tumor persistence after tyrosine kinase inhibition. Concomitant MYLK inhibition may enable the use of a lower dose of avapritinib, which is associated with dose-dependent cognitive side effects.

3 November 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
MEMark S. Etherington
Mark S. Etherington
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
MLMengyuan Liu
Mengyuan Liu
ATAndrew D. Tieniber
Andrew D. Tieniber
RDRonald P. DeMatteo
Ronald P. DeMatteo
γδ T cells are a rare but potent subset of T cells with pleiotropic functions. They commonly reside within tumors but the response of γδ T cells to tyrosine kinase inhibition is unknown. To address this, we studied a genetically engineered mouse model of gastrointestinal stromal tumor (GIST) driven by oncogenic Kit signaling that responds to the Kit inhibitor imatinib. At baseline, γδ T cells were antitumoral, as blockade of either γδ T-cell receptor or IL17A increased tumor weight and decreased antitumor immunity. However, imatinib therapy further stimulated intratumoral γδ T cells, as determined by flow cytometry and single-cell RNA sequencing (scRNA-seq). Imatinib expanded a highly activated γδ T-cell subset with increased IL17A production and higher expression of immune checkpoints and cytolytic effector molecules. Consistent with the mouse model, γδ T cells produced IL17A in fresh human GIST specimens, and imatinib treatment increased γδ T-cell gene signatures, as measured by bulk tumor RNA-seq. Furthermore, tumor γδ T cells correlated with survival in patients with GIST. Our findings highlight the interplay between tumor cell oncogene signaling and antitumor immune responses and identify γδ T cells as targets for immunotherapy in GIST.

4 April 2023
Verified
Other
Open access
ATAndrew D. Tieniber
Andrew D. Tieniber
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
GVGerardo A. Vitiello
Gerardo A. Vitiello
MEMark S. Etherington
Mark S. Etherington
RDRonald P. DeMatteo
Ronald P. DeMatteo
Supplementary Table from Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity

4 April 2023
Verified
Other
Open access
ATAndrew D. Tieniber
Andrew D. Tieniber
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
GVGerardo A. Vitiello
Gerardo A. Vitiello
MEMark S. Etherington
Mark S. Etherington
RDRonald P. DeMatteo
Ronald P. DeMatteo
Supplementary Figure from Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity

25 November 2025
Verified
Other
Open access
FRFerdinand Rossi
Ferdinand Rossi
MLMengyuan Liu
Mengyuan Liu
ATAndrew Tieniber
Andrew Tieniber
MEMark S. Etherington
Mark S. Etherington
AHAndrew Hanna
Andrew Hanna
RDRonald P. DeMatteo
Ronald P. DeMatteo
Supplemental Figure 2. GIST PDGFRA D842V PDXs are not sensitive to imatinib.